Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B-Reference-Cited by-同舟云学术

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B

Published:2018-10 Issue:10 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wijnant Gert-Jan¹²,Van Bocxlaer Katrien¹,Fortes Francisco Amanda³,Yardley Vanessa¹,Harris Andy⁴,Alavijeh Mo⁴,Murdan Sudaxshina²,Croft Simon L.¹

Affiliation:

1. Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

2. Department of Pharmaceutics, UCL School of Pharmacy, London, United Kingdom

3. Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

4. Pharmidex Pharmaceutical Services Ltd., London, United Kingdom

Abstract

Disfiguring skin lesions caused by several species of the Leishmania parasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate antibiotic concentrations at the dermal site of infection within the inflamed skin.

Funder

EC | Horizon 2020 Framework Programme

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00631-18

Reference65 articles.

1. Social and Economic Burden of Human Leishmaniasis

2. Leishmaniasis Worldwide and Global Estimates of Its Incidence

3. Cutaneous Manifestations of Human and Murine Leishmaniasis